Frequent drug safety alarm and drug safety events caused both great attention of the whole society and reflect pharmaceutical industry on how to enhance the awareness of social responsibility for pharmaceutical enterprises in China and establish a big social responsibility ecosphere in Chinese pharmaceutical industry.

On May 10, China Pharmaceutical Enterprises Association, China Chemical Pharmaceutical Industry Association, China Association for Medical Devices Industry, China Pharmaceutical Commerce Association, China Association of Traditional Chinese Medicine and China Nonprescription Medicines Association jointly carried out “Practice Guidelines to Corporate Social Responsibility for Pharmaceutical Enterprises in China" project and held project seminar in Beijing. More than 20 people participated it, including representatives of the above six associations, representatives of pharmaceutical enterprises such as Fosun Pharma, scholars and experts in the field of social responsibility, and relevant media.

The project means that pharmaceutical industry will establish a scientific and widely accepted social responsibility index system to form a healthy atmosphere of fulfilling social responsibility in the whole industry. Fosun Pharma actively cooperated with and participated in the project, and many other pharmaceutical enterprises also participated, including Hisun, Tasly, CSPC Pharma, Zhejiang Medicine, Luye Pharma, etc..

In the seminar, the six associations were consistent with support of "Practice Guidelines to Corporate Social Responsibility for Pharmaceutical Enterprises inChina" project and were willing to jointly promote the project to enable the formation of good atmosphere and environment of corporate social responsibility in the whole industry and ensure the sustainable and healthy development of the industry.

On behalf of the six associations, the President of China Pharmaceutical Enterprises Association Guo Yunpei said that "Practice Guidelines to Corporate Social Responsibility for Pharmaceutical Enterprises in China" project was actively accepted by Fosun Pharma, Hisun, Tasly, CSPC Pharma, Zhejiang Medicine, Luye Pharma, Kelun Pharma, SHINVA, Furen Medicines and other enterprises and was supported by RDPAC (R&D-based Pharmaceutical Association Committee), China Pfizer, Sanofi and other multinational pharmaceutical enterprises, and that scholars and experts from China National Institute of Standardization, China Pharmaceutical University and Beijing University of Chinese Medicine also shared the professional advises for "Practice Guidelines to Corporate Social Responsibility for Pharmaceutical Enterprises in China" project. All of these fully illustrated the common good corporate social responsibility is the consensus and aspirations of the whole pharmaceutical industry, which would definitely promote the healthy and sustainable development of the whole industry.

The Secretary General of China Association for Medical Devices Industry Zhao Yisu hoped that the seminar would form social responsibility guidelines commonly obeyed in the whole industry, form a long-term mechanism, and promote leading enterprises’ practice and the role of benchmarking. The executive president of China Chemical Pharmaceutical Industry Association Pan Guangcheng said that how to combine the standards of corporate social responsibility for pharmaceutical enterprises inChinaand the international standards needed for special thinking.

At the seminar, participants also discussed research ideas and methodology of the project. The deputy chief engineer of China National Institute of Standardization Quality Management Branch Chen Yuanqiao said the implementation of corporate social responsibility would experience a process, firstly letting enterprises to know such a standard, and then pharmaceutical enterprises would practice social responsibility based on a uniform standard. The future competition between enterprises would depend on not just technology but also the value concept. Enterprises should integrate social responsibility into the value concept as well as the development strategy of the enterprise.

A graduate teacher of Management College of Beijing University of Chinese Medicine Li Qi said pharmaceutical corporate social responsibility index system should break through the drawback of previous index system without specifically aiming at the characteristics of the pharmaceutical industry and that the new one should include a social responsibility index system with pharmaceutical industry features. Pharmaceutical corporate social responsibility index system should be formed through establishing index library to ensure a more scientific index establishment process.

When it comes to pharmaceutical enterprises’ exploration, experience and problems in terms of the implementation of social responsibility, the General Manager of Brand & Public Relations Department of Fosun Pharma Zhou Yiting said Fosun Pharma had released 8 CSR reports as a industry chain group in pharmaceutical industry. The longer corporate social responsibility, the heavier responsibility, the more meaningful. Corporate social responsibility was not a brochure concept, but a concept of system. Fosun Pharma was looking forwarding to "Practice Guidelines to Corporate Social Responsibility for Pharmaceutical Enterprises inChina". It was necessary for pharmaceutical industry to establish a sound industry specific index, so that pharmaceutical enterprises can be on the same platform to know their locations and gaps.

At the seminar, associations, enterprises and experts present also suggested to establish "Alliance of Corporate Social Responsibility for Pharmaceutical Enterprises inChina", carried out by “E Medicine Managers" for jointly promotion, revision and other follow-up works of "Practice Guidelines to Corporate Social Responsibility for Pharmaceutical Enterprises inChina". In future, during the launch and implementation of the project, Fosun Pharma would actively participate in, so as to promote higher and stricter standards of sustainable development.

Fosun Pharma always believes that a more harmonious ecosystem derives from corporate self-regulation. Fosun Pharma would always adhere to the principles of sustainable development and the mission of human health, serve as a model, constantly purify market environment of the whole pharmaceutical industry, so as to promote a healthier and more sustainable development of the industrial ecosystem.

Seminar of "Practice Guidelines to Corporate Social Responsibility for Pharmaceutical Enterprises in China" Project Was Held

Participants Photo

President of China Pharmaceutical Enterprises Association Guo Yunpei Made a Speech on behalf of Six Associations

The General Manager of Brand & Public Relations Department of Fosun Pharma Zhou Yiting Made a Speech